Phase 3 N=4,076 Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis
Herpes Labialis
Primary: Lesion Healing — 107.47; 110.08; 112.41 hours
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=2,020 A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally
Recurrent Herpes Labialis
Primary: Duration of Episode (DOE) Was Measured in Hours (Using the Science 37 Platform), of a Single Treated Herpes Labialis (HL) Lesion — 66.5; 73.6 Hours — p=0.716
Phase 1 N=54 Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis
Herpes Labialis
Primary: Subjects With at Least One Form of Contact With Study Staff With no Herpes Labialis Outbreaks Within 119 Days of Sensitization — 62.96; 20 percentage of particpants
Phase 2 N=242 Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus Infection
Oral Herpes Simplex
Primary: Proportion of Subjects Who Experience a New Cold Sore Outbreak That Proceeds to the Lesion Stage. Of Those Subjects That Take Study Medication (Experience a New Emerging…
Phase 2 N=139 Double-blind, Vehicle-controlled Study of the Efficacy and Safety of SADBE in Subjects With Recurrent Herpes Labialis
Herpes Labialis · Cold Sore
Primary: Days to Next Herpes Labialis (Cold Sore) Episode From 43 Days After the First Dose up to 121 Days After the First Dose — 128; 163; 174 days
Phase 1 N=36 Immune Response and General Immune Health in Subjects Infected With Herpes Simplex Virus Type 1 (HSV-1)
HSV · Herpes Labialis
Primary: Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline — 10.073; 11.380; 10.711; 11.431 q-RT-PCR crossing threshold cycle (Ct)
Phase 2 N=223 Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes
Herpes Labialis
Primary: Efficacy Measured by Percentage of Subjects With Non-ulcerative Lesions Based on Principal Investigator's Assessment — 21.8; 16.4; 19.9; 78.2 percentage of partcipants…
Phase 3 N=157 Zinc for the Treatment of Herpes Simplex Labialis (HSL)
Herpes Simplex Labialis
Primary: Zicam Was Compared to Placebo as a Treatment of Recurrent HSL From the Date and Time of the Initiation of Therapy Until the Date and Time of Resolution of the Lesion or…
Phase 3 N=53 Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis
Herpes Labialis
Primary: Number of Participants Reported Adverse Events (AEs), Serious Adverse Events (SAEs) — 6; 6; 0; 0 Participants
Phase 4 N=463 Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients
Genital Herpes
Primary: Investigator Assessed Time to Healing of All Non-aborted Genital Herpes Lesions — 5.38; 4.79 Days — p=0.4161
Phase 3 N=150 Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes
GENITAL HERPES
Primary: Efficacy Will be Evaluated by the Proportion of Subjects With Non Herpes Manifestation — 73; 52 subjects
Phase 4 N=126 A Comparative Study of the Efficacy of Penciclovir 10mg/g (1%) Cream in Preventing the Appearance of Classical Lesion in Recurrent Cold Sore Sufferers
Cold Sore
Primary: Clinical Assessment Performed by the Investigator and Skin Temperature at the Cold Sore. — 39; 32 participants
Phase 3 N=275 Open-label Study of ASP2151 in Herpes Simplex Patients
Herpes Simplex
Primary: Percentage of Participants With Healing by Day 8 — 194 Participants
Phase 3 N=775 Phase 3 Clinical Study for the Treatment of Cold Sore
Herpes Labialis
Primary: Time to Healing (TTH) of Vesicular Primary Lesion — 7.00; 7.32 Days — p=0.015
Phase 2 N=10 EDTA Eye Drops Compared to Abreva for Herpes Simplex Virus Eruptions
Herpes Simplex Oral
Primary: Duration (Days) of Herpes Labialis Outbreak Until Healed — 10.6; 8.25 days
Phase 3 N=54 Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old
Herpes Labialis
Primary: Reporting of Adverse Events — 9 participants
N/A N=103 Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding
HIV · HIV Infections
Primary: Herpes Simplex Virus Type 2 Recurrence — 0; 0 Recurrence
Phase 2 N=80 Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes
Herpes Simplex Type 2
Primary: Percent Change in Overall Viral Shedding Rate From Baseline (Week -7 to 0) to Post-treatment Period (Weeks 6 to 13) — 13.53 percentage change
Phase 4 N=48 A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation
Genital Herpes
Primary: Frequency of HSV-2 Total Shedding From the Genital Tract as Measured by PCR, Calculated Using a Per-day Shedding Rate in Participants Treated With Suppressive Acyclovir…
Phase 2 N=19 Herpes Simplex Type 1 Suppression in Hepatitis C
Chronic Hepatitis C Infection
Primary: Change in HCV RNA Viral Load — .24; .08 log(IU/mL) — p=0.05
Phase 4 N=383 A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
Herpes Genitalis
Primary: Percentage of Participants With Time to First GH Recurrence — 43; 71 Percentage of participants — p=<0.001
Phase 1 N=25 An Exploratory Study to Investigate the Inflammatory Response During a Cold Sore Episode
Herpes Labialis
Primary: Mean Change From Baseline in Blood Flow — 2558.65; 3470.13; 809.88; 960.86 Perfusion Units — p=0.3061
Phase 3 N=1,179 Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes
Genital Herpes
Primary: Investigator-assessed Time to Healing of All Non-aborted Genital Herpes Lesions — 4.25; 4.08 days
Phase 3 N=29 Acyclovir Herpes Simplex Virus (HSV) Skin, Eye, and Mouth
Herpes Simplex
Primary: Participants With Neurologic Impairment at 12 Months as Measured by a Bayley's Neuro-developmental Assessment.(Motor Scores) — 0; 3; 0; 0 Participants
N/A N=88 GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women
Genital Herpes
Primary: Time to Healing of Genital Lesions — 5.1; 6.0 Days
Phase 3 N=87 Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
Encephalitis
Primary: Survival With no or Mild Neuropsychological Impairment at 12 Months After Initiation of Study Medication as Measured by the Mattis Dementia Rating Scale (MDRS) — 28; 34…
N/A N=46 The VIBLOK SAfety and perFormancE Trial
HSV-2 Infection · Genital Herpes
Primary: Serious Adverse Device Effects — 0 Percentage SADE's
Phase 4 N=34 Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV
Genital Herpes · HIV Infection
Primary: The Quantity of HIV-1 RNA in Plasma While on 400 mg Twice Daily of Acyclovir Versus 1000 mg Twice Daily of Valacyclovir. — 4.08; 3.68 log10 copies/mL — p=<0.001
Phase 2 N=303 A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
Genital Herpes
Primary: Number of Participants With Solicited Local and Systemic ARs — 74; 75; 75; 74 Participants
Phase 4 N=31 Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
Genital Herpes
Primary: Frequency of HSV-2 Total Shedding From the Genital Tract as Measured by PCR, Calculated Using a Per-day Shedding Rate in Participants Treated With High-dose Acyclovir as…